• +1-646-491-9876
    • +91-20-67278686

    Search

    Post-Operative Pain-Pipeline Review H2 2017

    Post-Operative Pain-Pipeline Review H2 2017

    • Report Code ID: RW0001881457
    • Category Life Sciences
    • No. of Pages 191
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Post-Operative Pain-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain-Pipeline Review H2 2017 provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

    Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation age level of fear or anxiety surgical procedure personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Filing rejected/Withdrawn Phase III Phase II Phase I Preclinical Discovery and Unknown stages are 2 1 10 16 8 14 3 and 2 respectively. Similarly the Universities portfolio in Phase III and Preclinical stages comprises 1 and 1 molecules respectively.

    Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Post-Operative Pain-Overview 8
    Post-Operative Pain-Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Post-Operative Pain-Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Post-Operative Pain-Companies Involved in Therapeutics Development 29
    Abide Therapeutics Inc 29
    AcelRx Pharmaceuticals Inc 29
    Adynxx Inc 30
    AngioChem Inc 30
    Aoxing Pharmaceutical Company Inc 31
    Camurus AB 31
    Cara Therapeutics Inc 32
    Center Laboratories Inc 32
    Colby Pharmaceutical Company 33
    Cytogel Pharma LLC 33
    Dompe Farmaceutici SpA 34
    DURECT Corp 34
    Eupraxia Pharmaceuticals Inc 35
    EyeGate Pharmaceuticals Inc 35
    Fujimoto Pharmaceutical Corp 36
    GW Pharmaceuticals Plc 36
    Heron Therapeutics Inc 37
    Immupharma Plc 37
    Innocoll AG 38
    Insys Therapeutics Inc 38
    Lipocure Ltd 39
    Liquidia Technologies Inc 39
    Medtronic Plc 40
    Mundipharma International Ltd 40
    Novartis AG 41
    Orion Oyj 41
    Pacira Pharmaceuticals Inc 42
    PainReform Ltd 42
    PhytoHealth Corp 43
    PixarBio Corp 43
    Proteus SA 44
    Recro Pharma Inc 44
    Relmada Therapeutics Inc 45
    Serina Therapeutics Inc 45
    SteadyMed Therapeutics Inc 46
    Teikoku Pharma USA Inc 46
    The Medicines Company 47
    Trevena Inc 47
    Xigen SA 48
    Post-Operative Pain-Drug Profiles 49
    (bupivacaine hydrochloride + meloxicam) ER-Drug Profile 49
    (buprenorphine hydrochloride + granisetron hydrochloride) ER-Drug Profile 52
    A-100-Drug Profile 53
    ABD-1970-Drug Profile 54
    ANG-2002-Drug Profile 55
    ARX-04-Drug Profile 56
    AYX-1-Drug Profile 64
    brimapitide-Drug Profile 67
    bupivacaine hydrochloride-Drug Profile 71
    bupivacaine hydrochloride-Drug Profile 72
    bupivacaine hydrochloride-Drug Profile 73
    bupivacaine hydrochloride-Drug Profile 74
    bupivacaine hydrochloride SR-Drug Profile 77
    bupivacaine hydrochloride SR-Drug Profile 82
    buprenorphine hydrochloride-Drug Profile 83
    CAM-2048-Drug Profile 84
    carbamazepine-Drug Profile 85
    CPC-111-Drug Profile 86
    CPC-123-Drug Profile 87
    CT-044-Drug Profile 88
    Cyt-1010-Drug Profile 89
    dexamethasone acetate-Drug Profile 91
    dexmedetomidine hydrochloride-Drug Profile 97
    DF-2755A-Drug Profile 98
    difelikefalin-Drug Profile 99
    Drug to Agonize MOR1 for Pain-Drug Profile 109
    ECP-1014-Drug Profile 110
    fadolmidine hydrochloride-Drug Profile 112
    fentanyl-Drug Profile 113
    gonyautoxin-Drug Profile 114
    HTX-009-Drug Profile 115
    HYLP-002-Drug Profile 116
    IPP-102199-Drug Profile 117
    ketorolac tromethamine-Drug Profile 118
    lacosamide-Drug Profile 119
    levorphanol tartrate ER-Drug Profile 120
    MDT-10013-Drug Profile 122
    meloxicam-Drug Profile 123
    meloxicam ER-Drug Profile 128
    MR-309-Drug Profile 129
    nabiximols-Drug Profile 131
    nalbuphine hydrochloride-Drug Profile 138
    neosaxitoxin-Drug Profile 139
    oliceridine-Drug Profile 141
    PMZ-2010-Drug Profile 148
    RBM-004-Drug Profile 150
    ropivacaine-Drug Profile 151
    ropivacaine ER-Drug Profile 152
    SAF-312-Drug Profile 153
    SER-226-Drug Profile 154
    Small Molecule for Post-Operative Pain-Drug Profile 155
    Small Molecules to Inhibit COX for Postoperative Acute Pain-Drug Profile 156
    sufentanil citrate-Drug Profile 157
    tilidine hydrochloride-Drug Profile 165
    tramadol hydrochloride-Drug Profile 166
    URB-937-Drug Profile 167
    VVZ-149-Drug Profile 168
    XEN-105-Drug Profile 170
    Post-Operative Pain-Dormant Projects 171
    Post-Operative Pain-Discontinued Products 174
    Post-Operative Pain-Product Development Milestones 175
    Featured News & Press Releases 175
    Appendix 186
    Methodology 186
    Coverage 186
    Secondary Research 186
    Primary Research 186
    Expert Panel Validation 186
    Contact Us 186
    Disclaimer 187

    List of Tables

    Number of Products under Development for Post-Operative Pain H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Target H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Post-Operative Pain-Pipeline by Abide Therapeutics Inc H2 2017
    Post-Operative Pain-Pipeline by AcelRx Pharmaceuticals Inc H2 2017
    Post-Operative Pain-Pipeline by Adynxx Inc H2 2017
    Post-Operative Pain-Pipeline by AngioChem Inc H2 2017
    Post-Operative Pain-Pipeline by Aoxing Pharmaceutical Company Inc H2 2017
    Post-Operative Pain-Pipeline by Camurus AB H2 2017
    Post-Operative Pain-Pipeline by Cara Therapeutics Inc H2 2017
    Post-Operative Pain-Pipeline by Center Laboratories Inc H2 2017
    Post-Operative Pain-Pipeline by Colby Pharmaceutical Company H2 2017
    Post-Operative Pain-Pipeline by Cytogel Pharma LLC H2 2017
    Post-Operative Pain-Pipeline by Dompe Farmaceutici SpA H2 2017
    Post-Operative Pain-Pipeline by DURECT Corp H2 2017
    Post-Operative Pain-Pipeline by Eupraxia Pharmaceuticals Inc H2 2017
    Post-Operative Pain-Pipeline by EyeGate Pharmaceuticals Inc H2 2017
    Post-Operative Pain-Pipeline by Fujimoto Pharmaceutical Corp H2 2017
    Post-Operative Pain-Pipeline by GW Pharmaceuticals Plc H2 2017
    Post-Operative Pain-Pipeline by Heron Therapeutics Inc H2 2017
    Post-Operative Pain-Pipeline by Immupharma Plc H2 2017
    Post-Operative Pain-Pipeline by Innocoll AG H2 2017
    Post-Operative Pain-Pipeline by Insys Therapeutics Inc H2 2017
    Post-Operative Pain-Pipeline by Lipocure Ltd H2 2017
    Post-Operative Pain-Pipeline by Liquidia Technologies Inc H2 2017
    Post-Operative Pain-Pipeline by Medtronic Plc H2 2017
    Post-Operative Pain-Pipeline by Mundipharma International Ltd H2 2017
    Post-Operative Pain-Pipeline by Novartis AG H2 2017
    Post-Operative Pain-Pipeline by Orion Oyj H2 2017
    Post-Operative Pain-Pipeline by Pacira Pharmaceuticals Inc H2 2017
    Post-Operative Pain-Pipeline by PainReform Ltd H2 2017
    Post-Operative Pain-Pipeline by PhytoHealth Corp H2 2017
    Post-Operative Pain-Pipeline by PixarBio Corp H2 2017
    Post-Operative Pain-Pipeline by Proteus SA H2 2017
    Post-Operative Pain-Pipeline by Recro Pharma Inc H2 2017
    Post-Operative Pain-Pipeline by Relmada Therapeutics Inc H2 2017
    Post-Operative Pain-Pipeline by Serina Therapeutics Inc H2 2017
    Post-Operative Pain-Pipeline by SteadyMed Therapeutics Inc H2 2017
    Post-Operative Pain-Pipeline by Teikoku Pharma USA Inc H2 2017
    Post-Operative Pain-Pipeline by The Medicines Company H2 2017
    Post-Operative Pain-Pipeline by Trevena Inc H2 2017
    Post-Operative Pain-Pipeline by Xigen SA H2 2017
    Post-Operative Pain-Dormant Projects H2 2017
    Post-Operative Pain-Dormant Projects H2 2017 (Contd..1) H2 2017
    Post-Operative Pain-Dormant Projects H2 2017 (Contd..2) H2 2017
    Post-Operative Pain-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Post-Operative Pain H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Top 10 Routes of Administration H2 2017
    Number of Products by Stage and Top 10 Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Abide Therapeutics Inc
    AcelRx Pharmaceuticals Inc
    Adynxx Inc
    AngioChem Inc
    Aoxing Pharmaceutical Company Inc
    Camurus AB
    Cara Therapeutics Inc
    Center Laboratories Inc
    Colby Pharmaceutical Company
    Cytogel Pharma LLC
    Dompe Farmaceutici SpA
    DURECT Corp
    Eupraxia Pharmaceuticals Inc
    EyeGate Pharmaceuticals Inc
    Fujimoto Pharmaceutical Corp
    GW Pharmaceuticals Plc
    Heron Therapeutics Inc
    Immupharma Plc
    Innocoll AG
    Insys Therapeutics Inc
    Lipocure Ltd
    Liquidia Technologies Inc
    Medtronic Plc
    Mundipharma International Ltd
    Novartis AG
    Orion Oyj
    Pacira Pharmaceuticals Inc
    PainReform Ltd
    PhytoHealth Corp
    PixarBio Corp
    Proteus SA
    Recro Pharma Inc
    Relmada Therapeutics Inc
    Serina Therapeutics Inc
    SteadyMed Therapeutics Inc
    Teikoku Pharma USA Inc
    The Medicines Company
    Trevena Inc
    Xigen SA

    Request for Sample

    Report Url https://www.reportsweb.com//post-operative-pain-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//post-operative-pain-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//post-operative-pain-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments